Source comparison
CJC-1295 vs Hexarelin: Research Application Comparison
Primary Mechanism GHRH analog; amplifies endogenous GH pulses Ghrelin mimetic; triggers immediate GH release independent of GHRH CJC-1295 works within natural regulation; Hexarelin bypasses it entirely Half-Life 6–8 days (sustained release) 70–80 minutes (rapi
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GHRH analog; amplifies endogenous GH pulses
- Ghrelin mimetic; triggers immediate GH release independent of GHRH
- CJC-1295 works within natural regulation; Hexarelin bypasses it entirely
- Half-Life
- 6–8 days (sustained release)
- 70–80 minutes (rapid clearance)
- CJC-1295 allows weekly dosing; Hexarelin requires 2–3 doses daily
- IGF-1 Elevation
- Sustained for 6–8 days per dose
- Transient (returns to baseline within 24 hours)
- CJC-1295 builds cumulative anabolic environment; Hexarelin does not
- GH Amplitude
- Moderate (1.5–3× baseline pulses)
- High (10–15× baseline spikes)
- Hexarelin produces larger acute spikes; CJC-1295 produces stable elevation
- Receptor Desensitisation
- Minimal with standard dosing
- Rapid (evident within 7–14 days of daily use)
- CJC-1295 maintains efficacy long-term; Hexarelin requires cycling
- Dosing Frequency
- 1–2 times per week
- 2–3 times per day
- CJC-1295 suits low-maintenance protocols; Hexarelin requires precise timing
- Ideal Research Context
- Long-duration studies, sustained anabolic signalling, IGF-1-dependent endpoints
- Acute response studies, pulsatile GH dynamics, receptor pharmacology
- Match peptide to study duration and endpoint type